logo-loader

Dyadic working with global research partners to express potential coronavirus vaccines using C1

Published: 02:08 16 May 2020 AEST

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb tells Proactive the Florida-based biotech is 'delivering on its promises.' Emalfarb says it saw a busy first quarter where the company stepped up in the global fight against the coronavirus pandemic.

Emalfarb says among its recent achievements, the company is working with worldwide research partners to leverage its proprietary C1 technology to express an increasing number of potential coronavirus vaccines and antibody candidates.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

10 hours, 52 minutes ago